Table 1.

Summary of the experiments performed with TGF-β1 inhibitors.

Study	Strain	Drug	Dosage	VS2–20 noise level/duration
Safety	MF1, C57	P17, P144	2.5 mg/kg/24 h/15 days	-
Pretreatment	MF1, C57	P17, P144	2.5 mg/kg/24 h /15 days	100 dB SPL/12 h
Treatment	C57	P17, P144	2.5 mg/kg/24 h /30 days	100 dB SPL /12 h
		P17, P144	2.5 mg/kg/12 h/15 days	100 dB SPL /30 min
		P17, P144	2.5 mg/kg/12 h/15 days	110 dB SPL /30 min
		P17, P144	2.5 mg/kg/12 h/15 days	120 dB SPL /30 min
	CBA	P144	10 mg/kg/24 h/ 15 days	110 dB SPL /30 min

Different mouse strains and doses were used to study cochlear toxicity and efficacy of TGF-β1 inhibitor peptides P17 and P144 in the treatment of NIHL. MF1, HsdOla:MF1; C57, C57BL/6JOlaHsd; CBA, CBA/CaOlaHsd; IP, intraperitoneal; VS^2–20, Violet Swept Sine noise, frequency range 2–20 kHz.